San Diego, CA -- (SBWIRE) -- 08/24/2016 -- Certain directors of Bristol-Myers Squibb Co are under investigation over possible wrongdoing. The investigation was announced for current long-term investors in NYSE:BMY shares over potential breaches of fiduciary duties by certain directors at Bristol-Myers Squibb.

Investors who purchased shares of Bristol-Myers Squibb Co (NYSE:BMY) and currently hold any of those NYSE:BMY shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm concerns whether certain Bristol-Myers Squibb Co officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

In October 2015, Bristol-Myers Squibb Co reached a civil settlement with the Securities and exchange Commission ("SEC") of alleged Foreign Corrupt Practices Act (FCPA) violations in which the Company agreed to approximately $14.7 million in disgorgement, penalties and interest.

Bristol-Myers Squibb Co reported that its annual Total Revenue rose from over $15.87 billion in 2014 to over $16.56 billion in 2015 while its Net Income declined from over $2 billion in 2014 to over $1.56 billion in 2015. Shares of Bristol-Myers Squibb Co (NYSE:BMY) declined from $76.30 per share on August 1, 2016 to as low as $58.07 per share on August 17, 2016.

On August 23, 2016, NYSE:BMY shares closed at $59.86 per share.

Those who purchased shares of Bristol-Myers Squibb Co have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com